Latest Press Releases
18 August 2022
For UK medical/trade/consumer media only: The National Institute for Health and Care Excellence issues positive Appraisal Consultation Document for Eisai’s Kisplyx® (lenvatinib) in combination with MSD’s Keytruda® (pembrolizumab) for first-line treatment of intermediate and poor risk advanced renal cell carcinoma
pdf - 257 KB
13 June 2022
